EP1011330A4 - Central nervous system axon regeneration - Google Patents

Central nervous system axon regeneration

Info

Publication number
EP1011330A4
EP1011330A4 EP98943195A EP98943195A EP1011330A4 EP 1011330 A4 EP1011330 A4 EP 1011330A4 EP 98943195 A EP98943195 A EP 98943195A EP 98943195 A EP98943195 A EP 98943195A EP 1011330 A4 EP1011330 A4 EP 1011330A4
Authority
EP
European Patent Office
Prior art keywords
nervous system
central nervous
axon regeneration
system axon
regeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98943195A
Other languages
German (de)
French (fr)
Other versions
EP1011330A1 (en
Inventor
Stephen M Strittmatter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of EP1011330A1 publication Critical patent/EP1011330A1/en
Publication of EP1011330A4 publication Critical patent/EP1011330A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP98943195A 1997-08-13 1998-08-12 Central nervous system axon regeneration Withdrawn EP1011330A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5526897P 1997-08-13 1997-08-13
US55268P 1997-08-13
PCT/US1998/016794 WO1999008533A1 (en) 1997-08-13 1998-08-12 Central nervous system axon regeneration

Publications (2)

Publication Number Publication Date
EP1011330A1 EP1011330A1 (en) 2000-06-28
EP1011330A4 true EP1011330A4 (en) 2001-05-16

Family

ID=21996779

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98943195A Withdrawn EP1011330A4 (en) 1997-08-13 1998-08-12 Central nervous system axon regeneration

Country Status (5)

Country Link
EP (1) EP1011330A4 (en)
JP (1) JP2001515018A (en)
AU (1) AU735607B2 (en)
CA (1) CA2300878A1 (en)
WO (1) WO1999008533A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214841A1 (en) * 1997-10-31 1999-04-30 Lisa Mckerracher Rho antagonists and their use to block inhibition of neurite outgrowth
US7169783B2 (en) 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
CA2325842C (en) 2000-11-02 2007-08-07 Lisa Mckerracher Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
DE10064195A1 (en) * 2000-12-22 2002-07-11 Migragen Ag Use of a composition for stimulating nerve growth, inhibiting scar tissue formation and / or reducing secondary damage
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
US7795218B2 (en) 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
AU2002335824A1 (en) 2001-10-12 2003-04-22 Case Western Reserve University Neuronal regeneration
EP1334729A1 (en) * 2002-02-07 2003-08-13 Botulinum Toxin Research Associates, Inc. Therapeutic use of non-neurotoxic clostridium botulinum toxin type C2
AU2003281152A1 (en) * 2002-07-12 2004-02-02 Yihai Cao A method for inhibiting vascular permeability and tissue edema
GB0216865D0 (en) * 2002-07-19 2002-08-28 Microbiological Res Authority Targetted agents for nerve regeneration
EP2002005A4 (en) * 2006-03-17 2009-12-09 Univ Mcgill Identification of crmp4 as a convergent regulator of axon outgrowth inhibition
WO2014113539A1 (en) * 2013-01-16 2014-07-24 Bal Ram Singh Botulinum chimera compositions for axonal regenerative therapy during spinal cord injury
KR102613528B1 (en) 2015-04-28 2023-12-12 미쓰비시 타나베 파마 코퍼레이션 RGMa BINDING PROTEIN AND USE THEREOF
US20180271911A1 (en) * 2015-10-02 2018-09-27 The Regents Of The University Of California Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5661033A (en) * 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
WO1995015765A1 (en) * 1993-12-07 1995-06-15 The General Hospital Corporation Peptides to overcome inhibition of nerve growth

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
K. JALINK, E.J. VAN CORVEN ET AL.: "Inhibition of lysophosphatidate-and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein rho", JOURNAL OF CELL BIOLOGY, vol. 126, no. 3, August 1994 (1994-08-01), pages 801 - 810, XP002915256 *
MARTIN F.B.G. GEBBINK, ET AL.: "Identification of a novel, putative rho-specific GDP/GTP exchange factor and a rhoA-binding protein: control of neuronal morphology", JOURNAL OF CELL BIOLOGY, vol. 137, no. 7, 30 July 1997 (1997-07-30), pages 1603 - 1613, XP000984783 *
P. LAMOUREUX, ET AL.: "Rac is required for growth cone function but not neurite assembly", JOURNAL OF CELL SCIENCE, vol. 110, March 1997 (1997-03-01), pages 635 - 641, XP000984782 *
R. KOZMA, ET AL.: "Rho family GTPases and neuronal growth cone remodelling: Relationship between increased complexity induced by cdc42Hs, Rac1, and acetylcholine and collapse induced by rhoA and lysophosphatidic acid", MOLECULAR AND CELLULAR BIOLOGY, vol. 17, no. 3, March 1997 (1997-03-01), pages 1201 - 1211, XP000984781 *
See also references of WO9908533A1 *

Also Published As

Publication number Publication date
JP2001515018A (en) 2001-09-18
EP1011330A1 (en) 2000-06-28
AU735607B2 (en) 2001-07-12
CA2300878A1 (en) 1999-02-25
AU9104298A (en) 1999-03-08
WO1999008533A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
ZA962759B (en) Catalysts
GB9712459D0 (en) Secure database system
GB2311583A9 (en) Suspension system
IL122528A0 (en) Catalytic dna
EP0966384A4 (en) Bicycle suspension system
PL336290A1 (en) Sulphonamides for treating endothelin-involving disorders
SG68599A1 (en) File system
DE69804447D1 (en) Lithographisches system
EP0902643A4 (en) Eeg based activation system
EP0915463A4 (en) Disc system
EP1011330A4 (en) Central nervous system axon regeneration
SG129998A1 (en) Compounds possessing neuronal activity
ZA987478B (en) Compounds possessing neuronal activity
IL129303A0 (en) Catalysts
PL325324A1 (en) Heasting system
GB2327649B (en) Suspension safety system
IL132143A0 (en) Identity system
GB2326779B (en) Fail-safe system
GB2345363B (en) File system block sub-allocator
HUP0002318A3 (en) Process for stimulating neural regeneration
GB9801699D0 (en) Pressure-compensation system
GB9720037D0 (en) Signalling system
GB9826404D0 (en) Bicycle suspension system
GB2324965B (en) Muscle restructuring system
EP1007064A4 (en) Regeneration of nerves in the central nervous system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010403

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20021216

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040518